Streetbeat News

Products Services

VXRT

Vaxart shares are trading higher after receiving a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study for its COVID-19 oral pill vaccine candidate.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:16 pm

AAPL

AMZN

AVGO

DIA

EBAY

MSFT

NVDA

QQQ

The article discusses the current surge in tech stocks driven by AI, comparing it to the dot-com bubble of the early 2000s. Companies like NVIDIA, Broadcom, Microsoft, and Apple are leading this trend, with the Nasdaq 100's performance surpassing the Dow Jones Industrial Average. Despite the high valuations, the fundamentals are stronger now than during the dot-com era, suggesting a less severe bubble risk.

Portfolio Pulse from Piero Cingari

June 13, 2024 | 8:16 pm

VXRT

Vaxart has received up to $453 million from BARDA for a Phase 2b study of its oral COVID-19 vaccine. The initial $65.7 million will fund the study start-up, with the remaining $387.2 million contingent on further study approval. Enrollment is expected to begin in summer 2024, with interim analysis by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:16 pm

OCUL

Ocular Therapeutix has enrolled 151 subjects in the SOL-1 pivotal study of AXPAXLI for wet AMD and plans a repeat dosing study (SOL-R). The 48-week HELIOS NPDR study results show significant improvement in patients treated with AXPAXLI.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:10 pm

AILE

iLearningEngines has launched the Microverse AI Engine in collaboration with UL Technology Solutions. This AI-powered platform aims to revolutionize content creation and training for over 450 employees.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:08 pm

INAB

IN8bio shares are trading higher after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:02 pm

INAB

IN8bio presented Phase 1 INB-100 trial data at EHA 2024, showing 100% of evaluable leukemia patients remain alive, progression-free, and in durable complete remission through one year. The trial demonstrated in vivo expansion and persistence of haplo-matched allogeneic gamma-delta T cell therapy.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 8:02 pm

TFX

The FDA has classified the recall of Teleflex/Arrow International's Arrow FiberOptix and UltraFLEX Intra-Aortic Balloon Catheter Kits as a Class I recall due to a manufacturing issue. This issue has been potentially linked to 31 injuries and 3 deaths.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 7:46 pm

NVDA

SMCI

Super Micro Computer, Inc. (NASDAQ:SMCI) shares surged by 12.4% due to strong performance in the AI sector and recent product innovations, including a liquid-cooled AI data center optimized for NVIDIA Corp (NASDAQ:NVDA) AI Enterprise software. The company reported a 37.09% year-over-year revenue growth, net income of $402.46 million, and earnings per share of $7.13.

Portfolio Pulse from Vaishali Prayag

June 13, 2024 | 7:43 pm

GME

MSTR

Bitcoin influencer Max Keiser suggested that GameStop (NYSE:GME) could push its stock price to $1,000 by adopting a Bitcoin treasury strategy similar to MicroStrategy's. This proposal has sparked discussions about the potential financial gains and risks of such a move.

Portfolio Pulse from Khyathi Dalal

June 13, 2024 | 7:39 pm